CLINICAL DEVELOPMENT OF CCR2 ANTAGONISTS CCX140-B AND CCX872-B

被引：0

作者：

Bekker, Pirow ^{[1
]}

Charvat, Trevor ^{[1
]}

Miao, Shichang ^{[1
]}

Dairaghi, Dan ^{[1
]}

Lohr, Lisa ^{[1
]}

Sullivan, Timothy ^{[1
]}

Seitz, Lisa ^{[1
]}

Miao, Zhenhua ^{[1
]}

Powers, Jay ^{[1
]}

Jaen, Juan ^{[1
]}

Schall, Thomas ^{[1
]}

机构：

[1] ChemoCentryx Inc, Mountain View, CA USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2013年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

页码：17 / 17

页数：1

共 50 条

[1] Phase 1 Clinical Evaluation of the CCR2 Antagonist CCX872-B
Bekker, Pirow
Charvat, Trevor
Miao, Shichang
Lohr, Lisa
Sullivan, Timothy
Miao, Zhenhua
Powers, Jay
Jaen, Juan
Schall, Thomas J.
DIABETES, 2013, 62 : A292 - A293
[2] Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.
Noel, Marcus Smith
Hezel, Aram F.
Linehan, David
Wang-Gillam, Andrea
Eskens, Ferry
Sleijfer, Stefan
Desar, Ingrid
Erdkamp, Frans
Wilmink, Johanna
Diehl, Janet
Potarca, Antonia
Zhao, Niky
Deng, Jun
Lohr, Lisa
Miao, Shichang
Charo, Israel
Singh, Rajinder
Schall, Thomas J.
Bekker, Pirow
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[3] CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice
Sullivan, Timothy
Miao, Zhenhua
Dairaghi, Daniel J.
Krasinski, Antoni
Wang, Yu
Zhao, Bin N.
Baumgart, Trageen
Ertl, Linda S.
Pennell, Andrew
Seitz, Lisa
Powers, Jay
Zhao, Ruiping
Ungashe, Solomon
Wei, Zheng
Boring, Landin
Tsou, Chia-Lin
Charo, Israel
Berahovich, Robert D.
Schall, Thomas J.
Jaen, Juan C.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 305 (09) : F1288 - F1297
[4] The inhibition of CCR2 to modify the microenvironment in pancreatic cancer mouse model and to support the profiling of the CCR2 inhibitor CCX872-B in patients.
Wang-Gillam, Andrea
Noel, Marcus Smith
Sleijfer, Stefan
Jung, Heiyoun
Lohr, Lisa
Zhao, Niky
Miao, Shichang
Potarca, Antonia
Charo, Israel
Bekker, Petrus
Schall, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[5] The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
de Zeeuw, Dick
Bekker, Pirow
Henkel, Elena
Hasslacher, Christopher
Gouni-Berthold, Ioanna
Mehling, Heidrun
Potarca, Antonia
Tesar, Vladimir
Heerspink, Hiddo J. Lambers
Schall, Thomas J.
LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (09): : 687 - 696
[6] Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 diabetes
Sullivan, T.
Miao, S.
Berahovich, R.
Zhao, N.
Ungashe, S.
Johnson, D.
Bekker, P.
Jean, J.
Schall, T. J.
DIABETOLOGIA, 2010, 53
[7] CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY
de Zeeuw, Dick
Henkel, Elena
Psottova, Jana
Paragh, Gyorgy
Mehling, Heidrun
Hasslacher, Christopher
Potarca, Antonia
Bekker, Pirow
Schall, Thomas J.
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
[8] Reduction of Liver Fibrosis by CCR2 antagonist CCX872 in Murine Models of NASH
Miao, Zhenhua
Newland, Dale
Ertl, Linda
Parker, Richard
McMahon, Jeff
Zhang, Penglie
Adams, David H.
Scholl, Thomas J.
Charo, Israel
HEPATOLOGY, 2016, 64 : 763A - 763A
[9] Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis
Parker, Richard
Walters, Matthew
Ertl, Linda
Ebsworth, Karen
Tan, Joanne
McMahon, Jeff
Powers, Jay
Adams, David
Jaen, Juan
Schall, Tom
LANCET, 2014, 383 : 78 - 78
[10] Reduction of Liver Fibrosis by CCR2 Antagonist CCX872 in Murine Models of NASH
Miao, Zhenhua
Newland, Dale
Ertl, Linda
Parker, Richard
McMahon, Jeff
Zhang, Penglie
Adams, David
Schall, Thomas
Charo, Israel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S398 - S398

← 1 2 3 4 5 →